Author:
Mandilaras Victoria,Bouganim Nathaniel,Yin Hui,Asselah Jamil,Azoulay Laurent
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Amaya K, Ohta T, Kitagawa H, Kayahara M, Takamura H, Fujimura T, Nishimura G, Shimizu K, Miwa K (2004) Angiotensin II activates MAP kinase and NF-kappaB through angiotensin II type I receptor in human pancreatic cancer cells. Int J Oncol 25: 849–856.
2. Anandanadesan R, Gong Q, Chipitsyna G, Witkiewicz A, Yeo CJ, Arafat HA (2008) Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling. J Gastrointest Surg 12: 57–66.
3. Arafat HA, Gong Q, Chipitsyna G, Rizvi A, Saa CT, Yeo CJ (2007) Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg 204: 996–1005;, discussion 1005-6.
4. Arnold SA, Rivera LB, Carbon JG, Toombs JE, Chang C, Bradshaw AD, Brekken RA (2012) Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFb activation. Plos One 7: 18.
5. Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, Gupta AK, Sever PS, Gluud C, Messerli FH (2011) Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials. Lancet Oncol 12: 65–82.
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献